Skip to main content
. 2024 Oct 8;4(10):2621–2637. doi: 10.1158/2767-9764.CRC-24-0304

Figure 2.

Figure 2

Efficacy of TKIs on tumor growth, in vitro and in vivo. A, Dose–response curve of axitinib, cabozantinib, and lenvatinib treatment of UM-RC-3 and RENCA VHL−, mean + SD, n = 5/group; control, 0 mmol/L TKIs, 1% DMSO; IC50 values of cell viability are reported. B, Experimental design and timeline of treatment schedule. C and D, Response to TKIs by UM-RC-3 (C) and RENCA VHL− (D) tumor cells in tibiae at day 11 of treatment; representative bioluminescence images and quantification are shown, mean ± SEM, n = 16 tibiae/group. E, Response of tumor cells in lungs to TKIs at day 11 of treatment; representative bioluminescence images and quantification are shown, mean ± SEM, n = 8/group. F, Stereomicroscope images of lungs (brightfield and GFP–green); Bar, 1 cm. P values by one-way ANOVA with Tukey honestly significant difference post hoc test; *, P < 0.05; **, P < 0.01; ***, P < 0.001. Axi, axitinib; Cabo, cabozantinib; Conc, concentration; Lenv, lenvatinib; Veh, vehicle.